United States Patent 6,280,705: What the claims actually cover, where the edges are, and how to map infringement and risk
What is U.S. Drug Patent 6,280,705 claiming at a system level?
U.S. Patent 6,280,705 claims a system for producing an ultrasound image that relies on a kit to generate stabilized microbubbles in situ through reconstitution of dry microbubble precursors.
Core system concept (Claim 1)
The system includes:
- An ultrasound imaging apparatus
- A kit capable of producing a stabilized microbubble preparation comprising:
- An aqueous medium
- Dry microbubble precursors containing:
- a gas osmotic agent dispersed in a container (implicitly by the kit structure later made explicit)
- a generally spherical shell formed by two surfactants:
- First surfactant: a phospholipid or mixture with at least one acyl chain C10+
- Second surfactant: more water soluble than the first surfactant
- Functional requirement at reconstitution:
- upon reconstitution, second surfactant facilitates shell dissolution
- leaving the first surfactant surrounding the gas osmotic agent
- to form an osmotically stabilized microbubble
Claim 1 is the dominant independent claim because it ties together:
- the ultrasound imaging system, and
- the specific microbubble formulation mechanism (two-surfactant shell behavior during reconstitution).
What is the formulation mechanism that defines the invention’s boundary?
The claims define the stabilized microbubble formation around one distinguishing mechanism:
Two-surfactant, differential solubility shell behavior
- The dry precursors define a shell that includes:
- First surfactant (phospholipid C10+ acyl chain)
- Second surfactant (more water soluble)
- During reconstitution with aqueous medium:
- the second surfactant dissolves (explicitly: “facilitates shell dissolution”)
- the first surfactant remains to wrap the gas osmotic agent
- this yields the final microbubble with an osmotically stabilized shell.
This is not framed as “any dry microbubble” or “any stabilized microbubble.” The claim requires the second surfactant’s relative solubility and shell dissolution outcome.
What does the patent claim cover in the kit (independent kit claim)?
What is the independent kit claim and how is it structured?
Claim 13 is the independent kit claim.
It recites:
- A container with dispersed therein a gas osmotic agent
- Dry microbubble precursors comprising:
- First surfactant: phospholipid (or mixture) with at least one C10+ acyl chain
- Second surfactant: “more water soluble than” the first surfactant
- Functional outcome:
- “plurality of stabilized microbubbles” forms by reconstituting precursors with aqueous medium
- second surfactant facilitates shell dissolution
- first surfactant surrounds gas osmotic agent
- osmotically stabilized microbubble in said container
Claims 1 and 13 track each other tightly:
- Claim 1 anchors the kit into an ultrasound system.
- Claim 13 anchors the kit itself.
What do the dependent claims narrow? (Gas osmotic agent, modifier gas, surfactants, and precursor form)
Which gas osmotic agents are within scope?
The claims provide extensive but enumerated lists.
Gas osmotic agent list (Claims 2, 4, 5, 9, 10, 12; and repeated across kit claims):
- perfluoropropane
- perfluorobutane
- perfluorocyclobutane
- perfluoromethylcyclobutane
- perfluoropentane
- perfluorocyclopentane
- perfluoromethylcyclopentane
- perfluorodimethylcyclobutanes
- perfluorohexane
- perfluorocyclohexane
- perfluoroheptane
- perfluorocycloheptane
- perfluoromethylcyclohexane
- perfluorodimethylcyclopentane
- perfluorotrimethylcyclobutane
- perfluorotriethylamine
Specific fallback selections appear as independent-enough dependent claims:
- perfluoropropane (Claims 4, 12, 16, 24, and others)
- perfluorobutane (Claims 5, 17, 29, and others)
- perfluorohexane (Claims 10, 22, 36, and others)
Practical claim boundary: if a competitor uses a gas osmotic agent outside these enumerated species, the asserted literal scope for these dependent claim positions is constrained.
What is the modifier gas coverage?
The claims allow a modifier gas added such that microbubbles “further comprise” it.
Modifier gas options (Claims 3, 11, 15, 23, 37, 38):
- nitrogen
- oxygen
- carbon dioxide
- combinations
Specific modifier selection:
- nitrogen explicitly (Claim 38)
Scope effect: modifier gas is additive and does not replace the required gas osmotic agent.
What second surfactants are covered?
Second surfactant is the key “more water soluble” element that drives shell dissolution.
Covered by enumeration (Claims 6, 18, 30):
- fatty acid
- salt of a fatty acid
- sugar ester of a fatty acid
- polyoxypropylene-polyoxyethylene copolymer (poloxamer family)
- nonionic alkylglucoside
- polysorbate
- combinations
Explicit embodiment:
- poloxamer (Claims 7, 19, 33)
Which first surfactants are explicitly singled out?
While Claim 1 covers a broader class (phospholipid or mixture with C10+ acyl chain), the dependent claims narrow to specific phospholipids:
- dimyristoylphosphatidylcholine (DMPC)
- dipalmitoylphosphatidylcholine (DPPC)
This appears as:
- Claim 8 (system)
- Claim 20 (kit)
- Claim 34 (kit with precursor form)
Scope effect: even if a competitor uses a different C10+ phospholipid, dependent claim literal match may fail, but independent Claim 1/13 can still capture it if the C10+ acyl-chain condition is met.
What precursor formats expand kit coverage?
Does the patent claim any specific dry precursor manufacturing mode?
Yes. The kit has additional dependent claims that specify precursor form.
Spray dried microspheres (Claims 31)
- Claim 31 recites powdered material comprises spray dried microspheres.
Hydrophilic monomer or polymer (Claim 32)
- Claim 32 recites powdered material comprises a hydrophilic monomer or polymer.
Lyophilized phospholipid (Claim 39)
- Claim 39 recites powdered material comprises lyophilized phospholipid.
Diffusion-facilitated dissolution mechanism (Claim 25)
Claim 25 adds a more explicit “diffusion of second surfactant” mechanism:
- reconstitution is “facilitated by diffusion of said second surfactant from said powdered material upon addition of said aqueous medium.”
This claim:
- still requires first surfactant as a C10+ phospholipid shell ingredient
- still requires second surfactant more water soluble
- but adds a solid-state diffusion narrative that may matter in claim construction and in proving “second surfactant facilitates shell dissolution.”
How do the kit claims differ across Claim 13 vs Claim 25 vs later specialized precursors?
| Claim |
What it emphasizes |
Added boundary conditions |
| 13 |
Kit + container + dry precursors + solubility-driven shell dissolution |
baseline kit architecture |
| 25 |
Same core but emphasizes powdered material diffusion of second surfactant |
reconstitution mechanism becomes diffusion-driven |
| 31-32 |
Powder form (spray dried microspheres) + hydrophilic monomer/polymer |
manufacturing/form constraint |
| 39 |
Powder form includes lyophilized phospholipid |
manufacturing/form constraint |
For freedom-to-operate, these form-dependent claims create “narrow paths” of literal coverage for competitors using those specific powder formats.
Infringement mapping: what a design-around must likely avoid
What elements are mandatory across the broad independent claims (1 and 13)?
Literal coverage requires all of the following elements in combination:
- Ultrasound imaging system (Claim 1 only), or kit (Claim 13)
- Dry microbubble precursors reconstituted with aqueous medium
- Gas osmotic agent (enumerated options appear in dependents, but the concept is core)
- Shell defined by two surfactants:
- first: phospholipid (C10+ acyl chain)
- second: more water soluble
- Upon reconstitution:
- second surfactant facilitates shell dissolution
- first surfactant surrounds gas osmotic agent
- forms an osmotically stabilized microbubble
Design-around focus points
To avoid literal infringement, a strategy must likely disrupt at least one mandatory combination element:
- eliminate or alter the two-surfactant differential solubility + shell dissolution outcome
- replace the phospholipid C10+ acyl chain requirement
- remove the specific reconstitution-defined transformation where second surfactant dissolves leaving first surfactant as the shell around the osmotic agent
Because the claims are mechanism-functional (shell dissolution during reconstitution) as well as compositional, a competitor cannot rely only on swapping inert excipients if the functional shell behavior still matches.
Claim interaction: which dependent claims strengthen the risk profile
How the dependent claims broaden or narrow literal coverage
The dependent claims do two things:
- Add specificity (gas species, modifier gas, poloxamer, DMPC/DPPC, powder format)
- Create multiple literal “lanes” for infringement proof
If a competitor matches any one lane fully, it becomes easier to show infringement because the court can map each element directly to the enumerated options.
Examples of “high-signal” lanes:
- Poloxamer as second surfactant (Claims 7, 19, 33)
- DMPC or DPPC as first surfactant (Claims 8, 20, 34)
- perfluoropropane or perfluorobutane or perfluorohexane selections (multiple claims)
- spray dried microspheres (Claim 31)
- lyophilized phospholipid (Claim 39)
- diffusion-driven reconstitution (Claim 25)
Patent landscape analysis for 6,280,705: how to structure a competitive search
What this patent is “about” in landscape terms
U.S. 6,280,705 sits at the intersection of:
- microbubble ultrasound contrast composition
- osmotically stabilized microbubbles using a gas osmotic agent
- dry/powder microbubble precursors that are reconstituted
- a two-surfactant system where the second surfactant is more water soluble and drives shell dissolution, leaving the first surfactant as the microbubble shell
This profile implies that the most relevant surrounding filings for a landscape are those involving:
- dry or lyophilized microbubble formulations
- perfluorocarbon (and related) osmotic-agent microbubbles
- stabilizer/surfactant systems that change during reconstitution
- imaging systems combining a microbubble kit with ultrasound apparatus
How to read the claim set in the context of landscape collisions
The claim set’s breadth is not only chemical. It is functional:
- “upon reconstitution” and “second surfactant facilitates shell dissolution” make this more than a static composition claim.
- That pushes infringement and validity analysis toward the process and formulation behavior during hydration.
So, landscape scoring should prioritize patents that teach:
- dry microbubble shell precursors
- a deliberately designed second component that dissolves more readily upon reconstitution
- retention of a hydrophobic phospholipid layer around gas
Key Takeaways
- U.S. 6,280,705 claims a two-surfactant, reconstitution-driven route to osmotically stabilized microbubbles for ultrasound imaging, anchored by Claim 1 (system) and Claim 13 (kit).
- The invention’s boundary is the second surfactant’s higher water solubility and its shell-dissolution role during reconstitution, leaving the C10+ phospholipid to surround the gas osmotic agent.
- Dependent claims create multiple literal infringement “lanes” via enumerated gas osmotic agents, optional modifier gas, specific poloxamer second surfactants, explicit DMPC/DPPC first surfactants, and defined powder formats (spray dried microspheres, lyophilized phospholipid), plus a diffusion-forward mechanism (Claim 25).
- For design-around, the most consequential risk is matching the functional reconstitution outcome. Swapping excipients without altering the shell dissolution behavior is unlikely to avoid coverage if the same mechanism remains.
- Landscape searches should focus on patents covering dry/reconstitutable microbubbles with perfluorocarbon osmotic agents and reconstitution-driven surfactant phase or dissolution behavior that leaves a phospholipid shell.
FAQs
-
Is Claim 6,280,705 primarily a microbubble formulation patent or an ultrasound-use patent?
It is both: Claim 1 ties the microbubble kit to an ultrasound imaging system, while Claim 13 covers the kit itself without requiring the imaging apparatus.
-
What is the single most defining technical requirement?
The reconstitution process requires that the second surfactant is more water soluble and facilitates shell dissolution, leaving the first C10+ phospholipid surrounding the gas osmotic agent.
-
Does the patent require perfluoropropane specifically?
No. Perfluoropropane is one listed gas osmotic agent, with other perfluorocarbons enumerated across dependent claims.
-
Do the claims allow additional gases in the microbubbles?
Yes. Dependent claims add a modifier gas selected from nitrogen, oxygen, and carbon dioxide (or combinations).
-
Does the patent specify dry powder formats?
Yes. It includes dependent claims covering spray dried microspheres and lyophilized phospholipid, and Claim 25 emphasizes diffusion of second surfactant during reconstitution.
References
[1] U.S. Patent No. 6,280,705.
